A Safety, Tolerability, and Pharmacokinetic Study of 1- and 2-mL Injections of LY3074828 Solution Using Investigational Pre-filled Syringes and Investigational Autoinjectors in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Mirikizumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly
- 14 Sep 2018 Status changed from active, no longer recruiting to completed.
- 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.